Earlier studies investigating the effect of PRS on the absolute risks of breast and ovarian cancer risks of BRCA1 and BRCA2 mutation carriers demonstrated potential for risk stratification (13,17–19). This evidence concerns the gene BRCA2 and ovarian cancer.